Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Sankpal, Narendra V ^a   Mayfield, John D ^a   Willman, Mike W ^a   Fleming, Timothy P ^a,b   Gillanders, William E ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPITHELIAL CELL ADHESION MOLECULE; PHOSPHOPROTEIN; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; CELL ADHESION MOLECULE; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN GA733; TUMOR-ASSOCIATED ANTIGEN GA733;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; FEMALE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82355168570     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3070     Document Type: Article

References (53)

1. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007, 96:417-423. 10.1038/sj.bjc.6603494, 2360029, 17211480.
2. Litvinov SV, Bakker HA, Gourevitch MM, Velders MP, Warnaar SO. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun 1994, 2:417-428. 10.3109/15419069409004452, 7842256.
3. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004, 23:5748-5758. 10.1038/sj.onc.1207610, 15195135.
4. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004, 64:5818-5824. 10.1158/0008-5472.CAN-04-0754, 15313925.
5. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009, 11:162-171. 10.1038/ncb1824, 19136966.
6. Carpenter G, Red Brewer M. EpCAM: another surface-to-nucleus missile. Cancer Cell 2009, 15:165-166. 10.1016/j.ccr.2009.02.005, 19249674.
7. Sankpal NV, Willman MW, Fleming TP, Mayfield JD, Gillanders WE. Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res 2009, 69:753-757. 10.1158/0008-5472.CAN-08-2708, 19141643.
8. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Köchli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004, 86:207-213. 10.1023/B:BREA.0000036787.59816.01, 15567937.
9. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004, 35:122-128. 10.1016/j.humpath.2003.08.026, 14745734.
10. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979, 76:1438-1442. 10.1073/pnas.76.3.1438, 383267, 286328.
11. Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, Hayry P, Koprowski H. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982, 1:762-765.
12. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmüller G, Baeuerle PA, Dreier T. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 2002, 100:101-110. 10.1002/ijc.10443, 12115595.
13. Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 2005, 92:342-349. 2361858, 15655555.
14. Velders MP, Litvinov SV, Warnaar SO, Gorter A, Fleuren GJ, Zurawski VR, Coney LR. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994, 54:1753-1759.
15. Velders MP, van Rhijn CM, Briaire IH, Fleuren GJ, Warnaar SO, Litvinov SV. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res 1995, 55:4398-4403.
16. Ammons WS, Bauer RJ, Horwitz AH, Chen ZJ, Bautista E, Ruan HH, Abramova M, Scott KR, Dedrick RL. In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia 2003, 5:146-154. 1502400, 12659687.
17. de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF. ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 2004, 10:7555-7565. 10.1158/1078-0432.CCR-04-0729, 15569986.
18. Spizzo G, Obrist P, Ensinger C, Theurl I, Dunser M, Ramoni A, Gunsilius E, Eibl G, Mikuz G, Gastl G. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer 2002, 98:883-888. 10.1002/ijc.10270, 11948467.
19. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E, Lebrecht A, Siggelkow W, Weikel W, Schiffer-Petry I, Gebhard S, Pilch H, Gehrmann M, Lehr HA, Koelbl H, Hengstler JG, Schuler M. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 2008, 14:5849-5855. 10.1158/1078-0432.CCR-08-0669, 18794096.
20. Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat 2010, 123:701-708. 10.1007/s10549-009-0671-z, 3042397, 20012351.
21. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006, 94:128-135. 10.1038/sj.bjc.6602924, 2361083, 16404366.
22. Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Fukuchi M, Kuwano H. Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol 2007, 30:171-179.
23. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005, 92:1767-1772. 10.1038/sj.bjc.6602519, 2362035, 15870832.
24. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 2004, 10:2659-2669. 10.1158/1078-0432.CCR-1132-03, 15102668.
25. Went P, Dirnhofer S, Salvisberg T, Amin MB, Lim SD, Diener PA, Moch H. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol 2005, 29:83-88. 10.1097/01.pas.0000.146028.70868.7a, 15613858.
26. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006, 103:483-488. 10.1016/j.ygyno.2006.03.035, 16678891.
27. Varga M, Obrist P, Schneeberger S, Mühlmann G, Felgel-Farnholz C, Fong D, Zitt M, Brunhuber T, Schäfer G, Gastl G, Spizzo G. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 2004, 10:3131-3136. 10.1158/1078-0432.CCR-03-0528, 15131054.
28. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, Amberger A, Laimer K, Gastl G, Tzankov A, Spizzo G. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 2008, 61:31-35.
29. Basak S, Speicher D, Eck S, Wunner W, Maul G, Simmons MS, Herlyn D. Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst 1998, 90:691-697. 10.1093/jnci/90.9.691, 9586666.
30. Tai KY, Shiah SG, Shieh YS, Kao YR, Chi CY, Huang E, Lee HS, Chang LC, Yang PC, Wu CW. DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 2007, 26:3989-3997. 10.1038/sj.onc.1210176, 17213811.
31. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004, 101:10380-10385. 10.1073/pnas.0403954101, 478580, 15240889.
32. Sankpal NV, Fleming TP, Gillanders WE. Dual expression lentiviral vectors for concurrent RNA interference and rescue. J Surg Res 2009, 156:50-56. 10.1016/j.jss.2009.02.004, 19524940.
33. Herr I, Krilleke D, Debatin KM. A sensitive, non-radioactive and fast method for detection of JNK/SAPK activity in leukemic T cells. Leukemia 2000, 14:1859-1860. 10.1038/sj.leu.2401911, 11021762.
34. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 1996, 148:313-319. 1861604, 8546221.
35. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res 2000, 2:331-334. 10.1186/bcr77, 138654, 11250725.
36. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, Miller FR. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 2001, 65:101-110. 10.1023/A:1006461422273, 11261825.
37. Denzel S, Maetzel D, Mack B, Eggert C, Barr G, Gires O. Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer 2009, 9:402. 10.1186/1471-2407-9-402, 2784796, 19925656.
38. Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene 2007, 26:1-10. 10.1038/sj.onc.1209759, 16799638.
39. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3:859-868. 10.1038/nrc1209, 14668816.
40. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature 1989, 337:661-663. 10.1038/337661a0, 2537468.
41. Westwick JK, Weitzel C, Minden A, Karin M, Brenner DA. Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase. The J Biol Chem 1994, 269:26396-26401.
42. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001, 98:13681-13686. 10.1073/pnas.251194298, 61101, 11717429.
43. Hu YF, Li R. JunB potentiates function of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated interaction. Genes Dev 2002, 16:1509-1517. 10.1101/gad.995502, 186344, 12080089.
44. Langer S, Singer CF, Hudelist G, Dampier B, Kaserer K, Vinatzer U, Pehamberger H, Zielinski C, Kubista E, Schreibner M. Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol 2006, 27:345-352.
45. Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol 2006, 37:668-674. 10.1016/j.humpath.2006.01.022, 16733206.
46. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 2004, 23:8238-8246. 10.1038/sj.onc.1207889, 15378019.
47. Lu C, Shen Q, DuPre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene 2005, 24:6516-6524.
48. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 2008, 27:366-377. 10.1038/sj.onc.1210643, 17637753.
49. Wang J, Kuiatse I, Lee AV, Pan J, Giuliano A, Cui X. Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer Res 2010, 8:266-277. 10.1158/1541-7786.MCR-09-0221, 2824784, 20145041.
50. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, Lisanti MP, Pestell RG. c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 2010, 285:8218-8226. 10.1074/jbc.M110.100792, 2832973, 20053993.
51. Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M, Krobitsch S, Martowicz A, Gastl G, Spizzo G. Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer 2011, 11:45. 10.1186/1471-2407-11-45, 3042418, 21281469.
52. Morlon A, Sassone-Corsi P. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc Natl Acad Sci USA 2003, 100:3977-3982. 10.1073/pnas.0735923100, 153033, 12644711.
53. Maaser K, Borlak J. A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators. Br J Cancer 2008, 99:1635-1643. 10.1038/sj.bjc.6604725, 2584962, 19002182.